The CLEAN Mergers Act would substantially expand federal antitrust enforcement for large mergers and acquisitions under the Clayton Act. It creates a new section authorizing mandatory divestiture or separation remedies for certain transactions, especially those consummated during a defined covered period beginning January 20, 2025 and ending January 19, 2029. Transactions valued at $10 billion or more would face the strongest treatment: if completed before enactment, they would generally have to be divested unless the parties obtain a declaratory judgment exemption; if completed after enactment, the assets would have to be held separate to preserve independence and competition while agencies review them.
The bill also authorizes agencies or state attorneys general to review so-called “enforcement-lapse transactions” for signs of improper clearance or political influence, including alleged violations of federal criminal statutes, material misrepresentations, ex parte communications, conflicts of interest, lobbying by foreign principals, and other irregularities in the review process. If such conditions are found, the agencies could order divestiture of all transaction assets, and the parties would bear a heavy burden to avoid that remedy. The bill further requires preservation of communications and electronic records related to covered transactions, authorizes adverse inferences and sanctions for spoliation, and provides for appointment of a divestiture trustee if parties do not comply.
In addition to the new divestiture framework, the bill amends the Clayton Act’s statute of limitations for antitrust actions by extending it from four years to ten years. It also makes structural relief—divestiture, dissolution, or rescission—the presumptive remedy in declaratory judgment actions involving covered transactions, with disgorgement available only in limited circumstances. The bill includes a severability clause to preserve the rest of the law if any part is struck down.
The overall sentiment reflected by the bill text is strongly pro-enforcement and skeptical of large mergers, emphasizing competition, transparency, and remedies that unwind transactions rather than merely regulate them. Because there are no committee transcripts or votes provided, there is no recorded legislative debate or roll-call sentiment to assess beyond the sponsors’ apparent intent to tighten merger review and deter perceived lapses in enforcement.
The main points of contention likely concern the bill’s retroactive or quasi-retroactive treatment of already consummated transactions, the breadth of the conduct that can trigger divestiture, and the high level of discretion given to agencies and courts. Potential critics may object to the presumption of structural remedies, the expanded role of state attorneys general, the record-preservation and sanctions provisions, and the inclusion of political, lobbying, and foreign-influence factors in merger review. Supporters would likely argue these tools are necessary to prevent anticompetitive consolidation and to correct transactions that escaped meaningful scrutiny.
The bill would amend the Clayton Act by adding a new section 7B that creates mandatory divestiture and hold-separate requirements for certain large mergers, authorizes post hoc review of transactions consummated during a specified period, expands evidentiary and preservation obligations, and strengthens remedies and penalties for noncompliance. It also extends the Clayton Act’s limitations period for antitrust actions from four years to ten years, affecting enforcement timelines for federal and potentially state antitrust litigation. The bill would directly affect acquiring firms, target companies, their counsel and lobbyists, reviewing agencies, and state attorneys general, while giving courts and agencies broader authority to unwind transactions and impose sanctions.
The bill’s framing and structure indicate a strongly aggressive antitrust posture, favoring divestiture, structural remedies, and expanded enforcement authority over merger approval and post-merger conduct. No committee discussion or votes were provided, so there is no documented bipartisan or partisan floor sentiment in the materials. Based on the text alone, the bill appears designed to appeal to merger skeptics and antitrust reform advocates, while likely drawing opposition from business, dealmakers, and others concerned about regulatory uncertainty and retroactive remedies.
Likely points of contention include whether the bill improperly reaches completed transactions, whether the $10 billion threshold and other market-concentration tests are too rigid, and whether the bill gives agencies and courts too much power to unwind deals based on process concerns rather than competitive harm. Another major issue is the bill’s focus on political communications, lobbying, foreign influence, and ethical violations as triggers for divestiture, which critics may view as overbroad or prone to politicization. Supporters would likely argue these provisions are necessary to deter improper merger clearance and restore competition when enforcement has lapsed.